JP2011529492A - 薬物担体 - Google Patents

薬物担体 Download PDF

Info

Publication number
JP2011529492A
JP2011529492A JP2011521085A JP2011521085A JP2011529492A JP 2011529492 A JP2011529492 A JP 2011529492A JP 2011521085 A JP2011521085 A JP 2011521085A JP 2011521085 A JP2011521085 A JP 2011521085A JP 2011529492 A JP2011529492 A JP 2011529492A
Authority
JP
Japan
Prior art keywords
carrier
therapeutic composition
therapeutic
composition according
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011521085A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529492A5 (https=
Inventor
洋司郎 新津
ユ，レイ
ツァオ，ガン
ヴァン，サン
チェン，フー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of JP2011529492A publication Critical patent/JP2011529492A/ja
Publication of JP2011529492A5 publication Critical patent/JP2011529492A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011521085A 2008-07-30 2008-09-12 薬物担体 Pending JP2011529492A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US8495508P 2008-07-30 2008-07-30
US8497708P 2008-07-30 2008-07-30
US8496808P 2008-07-30 2008-07-30
US8493908P 2008-07-30 2008-07-30
US8494708P 2008-07-30 2008-07-30
US8496408P 2008-07-30 2008-07-30
US61/084,968 2008-07-30
US61/084,955 2008-07-30
US61/084,977 2008-07-30
US61/084,964 2008-07-30
US61/084,947 2008-07-30
US61/084,939 2008-07-30
PCT/US2008/076295 WO2010014117A1 (en) 2008-07-30 2008-09-12 Drug carriers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014019952A Division JP2014129364A (ja) 2008-07-30 2014-02-05 薬物担体

Publications (2)

Publication Number Publication Date
JP2011529492A true JP2011529492A (ja) 2011-12-08
JP2011529492A5 JP2011529492A5 (https=) 2012-03-22

Family

ID=40627040

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011521085A Pending JP2011529492A (ja) 2008-07-30 2008-09-12 薬物担体
JP2014019952A Pending JP2014129364A (ja) 2008-07-30 2014-02-05 薬物担体
JP2015228674A Pending JP2016104732A (ja) 2008-07-30 2015-11-24 薬物担体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014019952A Pending JP2014129364A (ja) 2008-07-30 2014-02-05 薬物担体
JP2015228674A Pending JP2016104732A (ja) 2008-07-30 2015-11-24 薬物担体

Country Status (11)

Country Link
US (2) US20100028416A1 (https=)
EP (1) EP2323693B1 (https=)
JP (3) JP2011529492A (https=)
KR (2) KR20140065017A (https=)
CN (1) CN102159247A (https=)
AU (1) AU2008359989A1 (https=)
CA (1) CA2732412C (https=)
ES (1) ES2657214T3 (https=)
RU (2) RU2505315C2 (https=)
TW (1) TW201004646A (https=)
WO (1) WO2010014117A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501963A (ja) * 2008-09-12 2012-01-26 日東電工株式会社 線維性疾患のイメージング剤
JP2015517491A (ja) * 2012-05-07 2015-06-22 日東電工株式会社 リンカーを有するポリマー結合体
JP2016520124A (ja) * 2013-05-27 2016-07-11 バイオリーダーズ コーポレーションＢｉｏｌｅａｄｅｒｓ Ｃｏｒｐｏｒａｔｉｏｎ ポリ−γ−グルタミン酸を含有する粘液分散または水和用組成物
JP2016520687A (ja) * 2013-04-26 2016-07-14 日東電工株式会社 ポリアニオン性ポリマー結合体からのエンドトキシンの減少
JP2016531733A (ja) * 2013-07-09 2016-10-13 クラリアント・インターナシヨナル・リミテツド 固形脂質ナノ粒子を含む標的有効成分放出製剤
JP2017516883A (ja) * 2014-04-07 2017-06-22 日東電工株式会社 疎水性薬物送達のための新規なポリマーベースのヒドロトロープ

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358223B2 (en) 2004-10-04 2008-04-15 Nitto Denko Corporation Biodegradable cationic polymers
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
JP2009221164A (ja) * 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
HUE056941T2 (hu) 2004-12-22 2022-04-28 Nitto Denko Corp Gyógyszerhordozó és gyógyszerhordozó kit fibrózis gátlására
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
US9572886B2 (en) * 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
TWI407971B (zh) 2007-03-30 2013-09-11 日東電工股份有限公司 Cancer cells and tumor-related fibroblasts
US20080312174A1 (en) * 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
CN101970012A (zh) 2007-09-14 2011-02-09 日东电工株式会社 药物载体
WO2011072082A2 (en) * 2009-12-09 2011-06-16 Nitto Denko Corporation Modulation of hsp47 expression
RU2635460C2 (ru) * 2010-06-17 2017-11-13 Нитто Денко Корпорейшн Средство для лечения фиброза почек
JP5950428B2 (ja) 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
CN102652835A (zh) * 2010-12-10 2012-09-05 邹长坪 缓释高分子维甲酸
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
EP2718261B1 (en) * 2011-06-08 2016-02-24 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing sirna activity
ES2708932T3 (es) 2011-06-21 2019-04-12 Nitto Denko Corp Agente inductor de apoptosis
KR102059054B1 (ko) * 2011-11-18 2019-12-24 닛토덴코 가부시키가이샤 장 섬유증 치료제
WO2014070723A1 (en) * 2012-10-30 2014-05-08 Particle Sciences, Inc. Drug delivery particle formulations with targeting moieties
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
JP6076076B2 (ja) 2012-12-21 2017-02-08 日東電工株式会社 組織再生促進剤
US20160193249A1 (en) * 2013-09-03 2016-07-07 William Marsh Rice University Treatment of inflammatory diseases by carbon materials
US11430024B2 (en) * 2013-09-04 2022-08-30 Amos M. Cohen System and method of providing a virtual guestbook
IN2013MU03918A (https=) * 2013-12-13 2015-09-25 Cipla Ltd
US9976142B2 (en) 2014-04-02 2018-05-22 Nitto Denko Corporation Targeting molecule and a use thereof
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
WO2015194522A1 (ja) 2014-06-17 2015-12-23 日東電工株式会社 アポトーシス誘導剤
RU2575925C1 (ru) * 2014-11-06 2016-02-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет тонких химических технологий имени М.В. Ломоносова" (МИТХТ им. М.В. Ломоносова) Тетравалентные неогликоконъюгаты с углеводным разветвляющим ядром и способ их получения
US10264976B2 (en) * 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
SG11201802073YA (en) * 2015-09-15 2018-04-27 Samyang Biopharmaceuticals Pharmaceutical composition containing anionic drug, and preparation method therefor
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
EP3432926A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
WO2018045239A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Carrier-pd-l1 binding agent compositions for treating cancers
RU2021128415A (ru) * 2016-09-06 2021-11-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
KR20230011473A (ko) 2016-09-06 2023-01-20 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Ｐｄ－ｌ１ 발현 암의 치료 방법
RU2703624C2 (ru) * 2017-11-10 2019-10-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Коаксиальные регулярные нано-мезоструктуры, способ их получения и способ получения микрокапсул из этих структур
US11590080B2 (en) 2017-12-18 2023-02-28 C.R. Bard, Inc. Drug-loaded biodegradable microbead compositions including drug-containing vesicular agents
US12558308B2 (en) 2017-12-18 2026-02-24 C.R. Bard, Inc. Drug-loaded biodegradable microbead compositions including drug-containing vesicular agents
CN112004528B (zh) * 2017-12-18 2023-01-03 巴德股份有限公司 载药微珠组合物、栓塞组合物和相关方法
KR20200087594A (ko) * 2019-01-11 2020-07-21 한국화학연구원 레티노익산을 포함하는 미립구형 서방출 제제 및 그의 제조방법
WO2021053163A1 (en) 2019-09-19 2021-03-25 Danmarks Tekniske Universitet Immune stimulating micelle composition
WO2021067914A1 (en) * 2019-10-03 2021-04-08 The Trustees Of Columbia University In The City Of New York Combination therapy for acute myeloid leukemia, myelodysplastic syndromes and other blood diseases and disorders
KR20220128568A (ko) * 2021-03-12 2022-09-21 주식회사 엑소스템텍 비타민 a로 표면개질된 엑소좀을 포함하는 간 섬유증 예방 또는 치료용 약학적 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507930A (ja) * 1996-03-12 2000-06-27 ピージー―ティーエックスエル・カンパニー・エル・ピー 水溶性パクリタキセルプロドラッグ
JP2001519762A (ja) * 1996-03-15 2001-10-23 セラテック・インコーポレーテッド Ｔリンパ球への巨大分子プロドラッグのターゲティング
JP2005507934A (ja) * 2001-10-30 2005-03-24 ネクター セラピューティックス エイエル，コーポレイション レチノイン酸の水溶性ポリマー結合体
WO2006068232A1 (ja) * 2004-12-22 2006-06-29 Sapporo Medical University 線維化抑制のための薬物担体および薬物担体キット
JP2010539245A (ja) * 2007-09-14 2010-12-16 日東電工株式会社 薬物担体

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH667874A5 (fr) * 1985-12-19 1988-11-15 Battelle Memorial Institute Polypeptide synthetique biodegradable et son utilisation pour la preparation de medicaments.
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
FR2664500B1 (fr) * 1990-07-13 1994-10-28 Lille Ii Universite Droit Sant Procede de preparation d'une lipoproteine modifiee par incorporation d'une substance active lipophile, lipoproteine modifiee ainsi obtenue et composition pharmaceutique ou cosmetique la contenant.
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
JP3631755B2 (ja) * 1994-03-23 2005-03-23 明治製菓株式会社 ポリオキシエチレン含有脂質二本鎖誘導体
US6326356B1 (en) * 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US6033849A (en) * 1995-05-26 2000-03-07 The Salk Institute For Biological Studies Method for isolation of extrachromosomal amplified genes
MX9700850A (es) * 1995-06-09 1997-09-30 Euro Celtique Sa Formulaciones y metodos para proporcionar anestesia local prolongada.
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US6183774B1 (en) * 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
WO1997035012A1 (en) * 1996-03-20 1997-09-25 Board Of Regents, The University Of Texas System Sensitization of her-2/neu overexpressing cancer cells to chemotherapy
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6683048B1 (en) * 1997-04-10 2004-01-27 Mcgill University Compounds and methods for stimulating gene expression and cellular differentiation
EP1019429A4 (en) * 1997-08-20 2001-08-08 Somagenics Inc ANTISENSE THERAPEUTIC PRODUCTS WITH IMPROVED BINDING PROPERTIES AND METHODS OF USE
US6399383B1 (en) * 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
DE19756235A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
US6596770B2 (en) * 2000-05-05 2003-07-22 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6093743A (en) * 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
ATE300947T1 (de) * 1998-12-18 2005-08-15 Scios Inc Behandlung von erkrankungen mit zystenbildung
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
FR2790405B1 (fr) * 1999-03-02 2001-04-20 Oreal Nanocapsules a base de polymeres dendritiques
EP1169038B9 (en) * 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6319510B1 (en) * 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
US6663606B1 (en) * 1999-10-28 2003-12-16 Scimed Life Systems, Inc. Biocompatible medical devices
US20020041898A1 (en) * 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
WO2001051127A1 (en) * 2000-01-12 2001-07-19 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CZ20022413A3 (cs) * 2000-01-31 2003-08-13 Pfizer Products Inc. Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4
WO2001079505A2 (en) * 2000-04-17 2001-10-25 Children's Hospital Research Foundation INHIBITION OF BONE TUMOR FORMATION USING ANTISENSE cDNA THERAPY
MXPA02010747A (es) * 2000-05-02 2003-03-10 Hoffmann La Roche Nuevos agonistas de retinoides selectivos.
US20040047910A1 (en) * 2000-07-07 2004-03-11 Christian Beckett Suppository and composition comprising at least one polyethylene glycol
US7485320B2 (en) * 2000-09-25 2009-02-03 Industrial Technology Research Institute Liposome for incorporating large amounts of hydrophobic substances
US6660034B1 (en) * 2001-04-30 2003-12-09 Advanced Cardiovascular Systems, Inc. Stent for increasing blood flow to ischemic tissues and a method of using the same
SE0101702D0 (sv) * 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
AU2002344234B2 (en) * 2001-05-31 2007-11-08 Miravant Pharmaceuticals, Inc. Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US20040122080A1 (en) * 2002-03-22 2004-06-24 Vivat-Hannah Valerie S Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
US6869591B2 (en) * 2002-03-26 2005-03-22 Barnes-Jewish Hospital Paramagnetic particles that provide improved relaxivity
AU2002347747A1 (en) * 2002-07-23 2004-02-09 Ardenia Investments Ltd. Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
CA2509955A1 (en) * 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations useful against hepatitis c virus infections
US20040138154A1 (en) * 2003-01-13 2004-07-15 Lei Yu Solid surface for biomolecule delivery and high-throughput assay
US8969543B2 (en) * 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
US7064127B2 (en) * 2003-12-19 2006-06-20 Mount Sinai School Of Medicine Of New York University Treatment of hepatic fibrosis with imatinib mesylate
US7284401B2 (en) * 2004-01-12 2007-10-23 Boston Scientific Scimed, Inc. Stent reducing system and device
US7304045B2 (en) * 2004-10-05 2007-12-04 Hsing-Wen Sung Nanoparticles for targeting hepatoma cells
CA2631704A1 (en) * 2005-12-05 2007-06-14 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
US7700541B2 (en) * 2006-04-06 2010-04-20 Nitto Denko Corporation Biodegradable cationic polymers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507930A (ja) * 1996-03-12 2000-06-27 ピージー―ティーエックスエル・カンパニー・エル・ピー 水溶性パクリタキセルプロドラッグ
JP2001519762A (ja) * 1996-03-15 2001-10-23 セラテック・インコーポレーテッド Ｔリンパ球への巨大分子プロドラッグのターゲティング
JP2005507934A (ja) * 2001-10-30 2005-03-24 ネクター セラピューティックス エイエル，コーポレイション レチノイン酸の水溶性ポリマー結合体
WO2006068232A1 (ja) * 2004-12-22 2006-06-29 Sapporo Medical University 線維化抑制のための薬物担体および薬物担体キット
JP2010539245A (ja) * 2007-09-14 2010-12-16 日東電工株式会社 薬物担体

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501963A (ja) * 2008-09-12 2012-01-26 日東電工株式会社 線維性疾患のイメージング剤
JP2015517491A (ja) * 2012-05-07 2015-06-22 日東電工株式会社 リンカーを有するポリマー結合体
JP2016520687A (ja) * 2013-04-26 2016-07-14 日東電工株式会社 ポリアニオン性ポリマー結合体からのエンドトキシンの減少
JP2016520124A (ja) * 2013-05-27 2016-07-11 バイオリーダーズ コーポレーションＢｉｏｌｅａｄｅｒｓ Ｃｏｒｐｏｒａｔｉｏｎ ポリ−γ−グルタミン酸を含有する粘液分散または水和用組成物
JP2016531733A (ja) * 2013-07-09 2016-10-13 クラリアント・インターナシヨナル・リミテツド 固形脂質ナノ粒子を含む標的有効成分放出製剤
JP2017516883A (ja) * 2014-04-07 2017-06-22 日東電工株式会社 疎水性薬物送達のための新規なポリマーベースのヒドロトロープ
US10080737B2 (en) 2014-04-07 2018-09-25 Nitto Denko Corporation Polymer-based hydrotropes for hydrophobic drug delivery

Also Published As

Publication number Publication date
JP2014129364A (ja) 2014-07-10
ES2657214T3 (es) 2018-03-02
RU2011107076A (ru) 2012-09-10
TW201004646A (en) 2010-02-01
JP2016104732A (ja) 2016-06-09
RU2505315C2 (ru) 2014-01-27
US20100028416A1 (en) 2010-02-04
CN102159247A (zh) 2011-08-17
US20140212474A1 (en) 2014-07-31
WO2010014117A1 (en) 2010-02-04
RU2013146387A (ru) 2015-04-27
AU2008359989A1 (en) 2010-02-04
EP2323693A1 (en) 2011-05-25
KR20140065017A (ko) 2014-05-28
EP2323693B1 (en) 2017-11-08
CA2732412A1 (en) 2010-02-04
CA2732412C (en) 2014-12-09
KR20110051214A (ko) 2011-05-17

Similar Documents

Publication Publication Date Title
EP2323693B1 (en) Drug carriers
Abdellatif et al. Approved and marketed nanoparticles for disease targeting and applications in COVID-19
Mottaghitalab et al. Targeted delivery system based on gemcitabine-loaded silk fibroin nanoparticles for lung cancer therapy
US8003621B2 (en) Drug carriers
Sun et al. Rational design of cancer nanomedicine: nanoproperty integration and synchronization
Ren et al. Carrier-free supramolecular hydrogel composed of dual drugs for conquering drug resistance
US11850309B2 (en) Cationic materials and formulations for drug delivery
Zhang et al. ATN-161 peptide functionalized reversibly cross-linked polymersomes mediate targeted doxorubicin delivery into melanoma-bearing C57BL/6 mice
Shim et al. Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy
Yu et al. Enhancing doxorubicin delivery toward tumor by hydroxyethyl starch-g-polylactide partner nanocarriers
Wang et al. Self-assembled indomethacin dimer nanoparticles loaded with doxorubicin for combination therapy in resistant breast cancer
KR20170086638A (ko) 약학 조성물, 이의 제조 및 용도
Hamsici et al. Gemcitabine integrated nano-prodrug carrier system
Yu et al. Self-assembled tumor-penetrating peptide-modified Poly (l-γ-glutamylglutamine)–paclitaxel nanoparticles based on hydrophobic interaction for the treatment of glioblastoma
RU2451509C1 (ru) Противоопухолевый препарат
CA2863307C (en) Retinoid-targeted drug carriers
HK1159504A (en) Drug carriers
Agnihotri et al. PEGylated Nanocarriers for Protein and Peptide Delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130826

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131105